rituximab,brentuximab vedotin
roche,biogen,takeda,seagen
['echelon-3']
dr. bartlett's poster (#35) on the safety and efficacy results from the safety run-in period of the phase 3 echelon-3 study, will be available in mccormick place, hall a, at 8am. #asco22 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network